REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS FOR RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) AND MONOCLONAL ANTIBODIES (MAB) THERAPIES

被引：0
|
作者：
Feng, C. [1 ]
Murphy, L. [2 ]
Engel-Nitz, N. [2 ]
Nguyen, A. [2 ]
Patel, A. [1 ]
DuCharme, M. [2 ]
Fu, C. [1 ]
Shah, G. [3 ]
机构：
[1] Kite Pharma, Santa Monica, CA USA
[2] Optum, Eden Prairie, MN USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD178
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [1] Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma
    Seyedin, Roxanna
    Snider, Julia T.
    Rajagopalan, Krithika
    Wade, Sally W.
    Gergis, Usama
    FUTURE ONCOLOGY, 2023, 19 (22) : 1535 - 1547
  • [2] Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
    Fitzgerald, Lindsey
    Kittai, Adam
    Nastoupil, Loretta J.
    Waller, Alexandra
    Jacobson, Caron A.
    Saucier, Anna
    Kamdar, Manali K.
    Spradley, Janet
    Denlinger, Nathan
    Chipman, Jonathan
    Hu, Boyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Liu, Fei Fei
    Subbiah, Krishnaveni
    Gu, Tao
    Le, Trong Kim
    BLOOD, 2022, 140 : 2414 - 2415
  • [4] Hospital Costs and Healthcare Resource Utilization (HRU) for Chimeric Antigen (CAR) T-Cell Therapy and Stem Cell Transplant (SCT) in Patients with Large B-Cell Lymphoma (LBCL) in the United States (US)
    Cui, Chendi
    Feng, Chaoling
    Rosenthal, Ning
    Wade, Sally W.
    Curry, Laura
    Fu, Christine
    Shah, Gunjan L.
    BLOOD, 2022, 140 : 2161 - 2162
  • [5] Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis
    Munoz, Javier
    Hu, Zhen-Huan
    Kanters, Steve
    Limbrick-Oldfield, Eve H.
    Miao, Harry
    Spooner, Clare
    Xu, Hairong
    Sanderson, Robin
    BLOOD, 2022, 140 : 4627 - 4629
  • [6] Healthcare Utilization and Costs in Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
    Denlinger, Nathan
    Huang, Ying
    Braunstein, Zachary
    Sigmund, Audrey
    Bajwa, Amneet
    Kapoor, Nilesh
    Agyeman, Akwasi
    Fisher, Scott
    Purdin, Zebulun
    Neal, Alison
    Yucebay, Filiz
    Roddy, Julianna
    Brammer, Jonathan
    William, Basem
    Saad, Ayman
    Penza, Sam
    Voorhees, Timothy
    Kittai, Adam
    de Lima, Marcos
    Vasu, Sumithira
    Jaglowski, Samantha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S381 - S382
  • [7] Real-world Treatment Patterns and Outcomes of Patients with Large B-cell Lymphoma (LBCL) Who Received Loncastuximab Tesirine Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
    Hamadani, Mehdi
    Lucero, Melanie
    DeVos, Jakob D.
    Keir, Chris
    Chen, Lei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S476 - S476
  • [8] Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
    Ernst, Moritz
    Oeser, Annika
    Besiroglu, Burcu
    Caro-Valenzuela, Julia
    Aziz, Mohamed Abd El
    Monsef, Ina
    Borchmann, Peter
    Estcourt, Lise J.
    Skoetz, Nicole
    Goldkuhle, Marius
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (09):
  • [9] Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
    Greenbaum, Uri
    Hashmi, Hamza
    Elsawy, Mahmoud
    Kim, Soyoung
    Moskop, Amy
    Awan, Farrukh T.
    Farooq, Umar
    Ganguly, Siddhartha
    Hematti, Peiman
    Jain, Michael D.
    Kebriaei, Partow
    Locke, Frederick L.
    Mead, Elena
    Nishihori, Taiga
    Olson, Amanda L.
    Pennisi, Martina
    Perales, Miguel-Angel
    Geethakumari, Praveen Ramakrishnan
    Shouval, Roni
    Shpall, Elizabeth J.
    Magalhaes-Silverman, Margarida Magalhaes
    Strouse, Christopher
    Turtle, Cameron J.
    Vallurupalli, Anusha
    Wudhikam, Kitsada
    Pasquini, Marcelo C.
    Ahmed, Sairah
    Sorror, Mohamed
    BLOOD, 2022, 140 : 4636 - 4638
  • [10] Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real-World Experience
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 9 - 10
12345